The cytokine and growth factor receptor landscape has long been defined by a handful of well-characterised pathways—each with its own established inhibitors and clinical applications. But the most compelling developments in this space are increasingly coming from targets that bridge multiple biological processes: receptors that link inflammation to angiogenesis, growth factors that drive both tumour vascularisation and immune evasion, and death receptors that are finally realising their potential as selective inducers of tumour cell apoptosis.
Among these multifaceted targets, IL6R , VEGFA , and TNFRSF10B represent three distinct pillars of modern cytokine and growth factor receptor research. IL6R is the master regulator of inflammation that has become an unexpected ally in overcoming chemoresistance and immune-related adverse events. VEGFA is the prototypical angiogenic factor that continues to yield surprises—from epigenetic regulation to CAR T-cell engineering. And TNFRSF10B (death receptor 5) is the apoptosis-inducing receptor that is finally moving from bench to bedside, with agonist antibodies and bispecific constructs now in active clinical development. Together, they illustrate the full spectrum of cytokine and growth factor receptor biology: from inflammation, to angiogenesis, to programmed cell death.
IL6R: The Inflammatory Hub That Drives Therapy Resistance—and How to Overcome It
Interleukin-6 (IL-6) and its receptor IL6R have long been recognised as central drivers of inflammation, but their role in cancer therapy resistance has only recently come into sharp focus. Elevated serum IL-6 levels are associated with poor prognosis during chemotherapy, and IL-6 has emerged as a critical mediator of chemoresistance through cancer stem cell enrichment and metastasis promotion via epithelial-mesenchymal transition (EMT) induction.
A 2025 study published in Pharmaceutics demonstrated a nanotechnology-enabled approach to overcome these challenges: tocilizumab-conjugated cisplatin nanoparticles (LPC-TCZ) that actively target IL6R while simultaneously inhibiting IL-6-mediated chemoresistance signalling pathways. The dual-action nanoplatform synergistically attenuated both EMT progression and cancer stem cell marker expression through targeted blockade of IL-6/STAT3 signalling, demonstrating superior tumour growth inhibition and metastatic suppression compared to conventional cisplatin monotherapy.
The implications of IL6R targeting extend well beyond chemotherapy. In head and neck squamous cell carcinoma, cancer-associated fibroblasts drive EMT-like changes and heightened radioresistance through IL-6 secretion, and these effects are robustly reversed using IL-6R and MAPK/ERK inhibitors. Notably, the IL-6/IL-6R/ERK pathway has been established as a central driver of disease progression in both HPV-positive and HPV-negative HNSCC models, distinguishing it from the classical IL-6/STAT pathway which affects only HPV-negative tumours.
VEGFA: The Angiogenic Driver That Keeps Revealing New Dimensions
If IL6R is the inflammatory hub, VEGFA is the angiogenic engine—and it continues to yield surprises more than two decades after the first anti-VEGF therapies were approved.
The classical view of VEGFA as simply a driver of tumour angiogenesis has given way to a far more nuanced understanding. A 2026 study published in BMC Cancer revealed that SMARCD1, a core subunit of the SWI/SNF chromatin remodelling complex, binds directly to the VEGFA promoter, enhancing chromatin accessibility and modifying histone marks to activate transcriptional expression. SMARCD1 knockdown sensitised bevacizumab-resistant clear cell renal cell carcinoma models to anti-angiogenic therapy, establishing the SMARCD1-VEGFA axis as a mechanistic foundation for novel precision therapies.
Resistance to anti-angiogenic therapy remains a major clinical challenge, but recent research has illuminated the underlying mechanisms. A 2026 study identified APOA2-mediated endothelial-to-mesenchymal transition and cancer lipid metabolism reprogramming as drivers of antiangiogenic drug resistance in hepatocellular carcinoma. Meanwhile, CPEB4 deficiency promotes vasculogenic mimicry and adaptive resistance to VEGF blockade, reducing reliance on VEGF-driven angiogenesis through an EMT-associated programme. These findings underscore that VEGFA research is far from a closed chapter—the biology of resistance continues to reveal new therapeutic entry points.
TNFRSF10B: The Death Receptor Finally Coming of Age
While IL6R and VEGFA operate in the realms of inflammation and angiogenesis, TNFRSF10B —also known as death receptor 5 (DR5) or TRAIL receptor 2—belongs to a fundamentally different category: the apoptosis-inducing receptors.
TNFRSF10B is a member of the tumour necrosis factor receptor superfamily and serves as the receptor for TRAIL (tumour necrosis factor-related apoptosis-inducing ligand). Unlike many other death receptors, TRAIL selectively induces apoptosis in a wide range of tumour cells—including liver cancer, lung cancer, breast cancer, and pancreatic cancer—while sparing normal tissues. This selectivity has made TNFRSF10B an exceptionally attractive target for therapeutic development.
The clinical translation of TNFRSF10B -targeting agents has accelerated significantly. Conatumumab (AMG 655) is a human monoclonal agonist antibody against TNFRSF10B that induces apoptosis via caspase activation, with binding affinities of 1 nM for the long form of DR5 and 0.8 nM for the short form. Agonistic antibodies, bispecific constructs, and small-molecule activators directed against TNFRSF10B are now under intense clinical development for both solid and haematological malignancies. The drug ozekibart (INBRX-109), a DR5 agonist antibody, has shown anti-tumour activity in solid tumours including non-small cell lung cancer and colorectal cancer, particularly when combined with chemotherapy or immune checkpoint inhibitors to enhance efficacy and reduce resistance risk.
Emerging bispecific approaches are further expanding the therapeutic potential of TNFRSF10B targeting. A 2026 study demonstrated tumour-selective regression through MUC16-guided DR5 clustering by the bispecific anti-MUC16×anti-DR5 antibody IMV-M™, illustrating how precision engineering can enhance the selectivity and potency of DR5 agonists. Beyond direct therapeutic applications, TNFRSF10B expression status and promoter methylation serve as prognostic and predictive biomarkers, making the receptor valuable not only as a therapeutic target but also as a diagnostic and stratification tool.
How to Choose and Buy?
At BOT Bioscience , we are committed to providing premium-quality Cytokine & Growth Factor Receptors to support your cutting-edge research in inflammation, angiogenesis, apoptosis, and therapeutic development. Our Cytokine & Growth Factor Receptors portfolio features:
· High purity and biological activity validated across multiple applications
· Broad coverage of cytokine receptors, growth factor receptors, and death receptors
· Multiple formats: recombinant proteins with various fusion tags (Fc, His, Avi, etc.) and antibodies in diverse clones and conjugations
· Multiple labelling options: biotin, APC, PE, FITC, and other fluorophores for multicolour flow cytometry and imaging
· Rigorous quality control for consistent batch-to-batch performance
· Custom protein expression, antibody development, and conjugation services upon request
For researchers interested in exploring Cytokine & Growth Factor Receptors for drug discovery, resistance mechanism studies, or immunotherapy research, BOT Bioscience offers comprehensive technical support and customisation services to meet your specific project requirements. Please Contact us or send an email at info@bot-bioscience.com for product inquiries, quotations, and more detailed information.